Brodeur G M, Seeger R C, Barrett A, Berthold F, Castleberry R P, D'Angio G, De Bernardi B, Evans A E, Favrot M, Freeman A I
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110.
J Clin Oncol. 1988 Dec;6(12):1874-81. doi: 10.1200/JCO.1988.6.12.1874.
Neuroblastoma is one of the most common tumors in childhood. However, it often has been difficult to compare clinical and laboratory studies of this disease due to a lack of uniform criteria for diagnosis, staging, and response. An international group of conferees addressed each of these issues and reached a consensus. Specific criteria for making a diagnosis of neuroblastoma are defined. A new neuroblastoma staging system is proposed that takes into account the most important elements of current but incompatible systems. Finally, criteria for response to treatment are standardized. The criteria proposed herein represent an international consensus of essentially every major pediatric oncology group or organization in the United States, Europe, and Japan. The staging system should be referred to as the International Neuroblastoma Staging System, and the response criteria as the International Neuroblastoma Response Criteria. Implementation of these criteria will greatly facilitate the comparison of clinical and laboratory studies by different groups and countries. Furthermore, these criteria should serve as a foundation on which future modifications or improvements can be based.
神经母细胞瘤是儿童期最常见的肿瘤之一。然而,由于缺乏统一的诊断、分期和反应标准,对该疾病的临床和实验室研究常常难以进行比较。一个国际会议小组讨论了上述每个问题并达成了共识。明确了神经母细胞瘤的诊断标准。提出了一种新的神经母细胞瘤分期系统,该系统考虑了当前但不兼容的系统中的最重要因素。最后,对治疗反应标准进行了标准化。本文提出的标准代表了美国、欧洲和日本基本上每个主要儿科肿瘤学小组或组织的国际共识。该分期系统应称为国际神经母细胞瘤分期系统,反应标准应称为国际神经母细胞瘤反应标准。这些标准的实施将极大地促进不同小组和国家之间临床和实验室研究的比较。此外,这些标准应作为未来修改或改进的基础。